Ivim Health is a telehealth weight-management service built around a monthly membership plus separate medication costs, and that split is the whole story of what you pay. The membership buys clinical access and provider visits. The drug is billed on its own, either through insurance, a manufacturer self-pay program, or a flat cash price for a compounded version. So the headline membership figure tells you little about your actual monthly total.
What are you actually paying for?
The recurring membership covers the clinical side: an initial visit, ongoing provider check-ins, dose adjustments, and messaging support. That is a reasonable thing to charge for, and it is roughly what other GLP-1 telehealth services charge for the same layer of care. Where the number swings is medication, which sits outside the membership.
If a member has insurance that covers weight-management drugs, branded semaglutide or tirzepatide may run through the pharmacy benefit, and the out-of-pocket cost depends on formulary tier and deductible. If coverage is denied, the alternatives are manufacturer self-pay pricing or a compounded medication at a fixed monthly rate. Most people shopping for Ivim end up comparing those last two, because a large share of commercial plans exclude anti-obesity medication as a category rather than as a single drug.
Which medications does Ivim prescribe?
Ivim works with GLP-1 and dual-agonist therapies, the same class that carries the strongest published evidence for weight management. Semaglutide is the most studied of the group. In the STEP 3 trial, semaglutide paired with intensive behavioral therapy produced substantially greater weight loss than behavioral therapy alone, and the results were published in JAMA in 2021. A separate head-to-head, the STEP 8 trial, compared weekly semaglutide against daily liraglutide and reported that semaglutide led to greater weight reduction. For the broader class in type 2 diabetes, the evidence base is summarized in a widely cited review of drugs for type 2 diabetes.
One point worth setting straight early: the evidence above applies to the FDA-approved branded products. When a service dispenses a compounded version, the molecule may be the same, but the specific product has not been through the approval process that generated those trials.
Where does compounded medication fit, and what is the fine print?
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than manufactured under an approved application. The FDA is direct about the distinction in its guidance on compounding: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness, or quality before they reach patients. That is a fact about the product, and it belongs in any honest review.
The safety record for compounded GLP-1 products is not just theoretical. A pharmacovigilance analysis of the FDA adverse event reporting system, published in 2025, examined safety signals tied to compounded GLP-1 receptor agonists. Separately, a poison control case series documented real administration errors with compounded semaglutide, many involving people drawing the wrong dose from vials. A clinical overview aimed at prescribers, published in 2025, walks through what providers need to know about compounded semaglutide, including sourcing and concentration variability.
None of this makes compounded medication automatically wrong. It makes the supervision, the pharmacy, and the labeling matter a great deal. What a compounded route offers is a predictable monthly cash price without insurance in the loop. What it gives up is the regulatory assurance behind an approved product. That trade is reasonable for some people and not for others, and it is a conversation for a prescriber, not a checkout page.
How does Ivim compare to other telehealth options?
| Service | Model | Medication approach |
|---|---|---|
| Ivim Health | Monthly membership, medication billed separately | Branded via coverage or self-pay, plus compounded options |
| Ro | Membership with insurance navigation | Branded GLP-1 focus, insurance-first |
| Hims and Hers | Subscription | Has offered compounded and branded routes |
| LillyDirect | Manufacturer channel | Branded tirzepatide, self-pay pricing |
| NovoCare | Manufacturer channel | Branded semaglutide, self-pay pricing |
The pattern here is that the manufacturer channels sell one company’s branded drug at a fixed cash price, while the membership services add clinical support and, in some cases, a compounded alternative. Ivim sits in that second group. For a plain-language breakdown of how Ivim structures its programs, the write-up as FormBlends explains lays out the membership and medication split alongside other supervised telehealth practices that publish flat monthly pricing.
Is Ivim worth it?
For someone whose insurance covers weight-management medication, a membership service is often unnecessary overhead. The pharmacy benefit and a local prescriber can deliver the same branded drug, and the membership fee becomes a cost with no clear return. In that situation, checking coverage first and skipping the subscription is the more sensible move.
For a cash payer who wants structured follow-up and dose management, the model makes more sense, provided the fine print is read closely. The questions that matter are whether the medication is branded or compounded, what the medication costs on top of the membership, and what the cancellation and refill terms look like. A low membership fee attached to an expensive or loosely sourced compounded drug is not a deal.
What about stopping the medication?
Any weight-management program should be honest about what happens after. The STEP 1 trial extension tracked participants after semaglutide was withdrawn and found that most of the lost weight returned over the following year, along with a reversal of related cardiometabolic gains. The STEP 4 trial reinforced the point from the other direction, showing that continuing semaglutide preserved weight loss while switching to placebo led to regain. This is a long-term commitment, and any service selling short introductory pricing should be evaluated on the sustainable monthly cost, not the first month.
Key takeaways
- Ivim’s membership fee and its medication cost are separate, and the drug is the bigger variable.
- Compounded GLP-1 medication is not FDA-approved and carries documented dosing and safety concerns.
- People with real coverage may not need a membership service at all.
- Weight regain after stopping is well documented, so plan for the long-term cost.
See also: The Importance of Business Ethics
Frequently asked questions
What does Ivim Health actually charge?
Ivim runs a membership model with a monthly program fee, and medication is billed separately. Branded drugs run through insurance or manufacturer self-pay, while compounded options carry a flat cash price. The all-in monthly figure depends on which medication route a member ends up on.
Does Ivim prescribe brand-name Wegovy and Zepbound or compounded drugs?
Both are possible depending on eligibility and supply. Ivim can route members toward branded semaglutide or tirzepatide, and it has also offered compounded versions, which are not FDA-approved products even when they contain the same active molecule.
Is compounded medication from a telehealth service safe?
Compounded GLP-1 medication is not FDA-approved and has documented safety and dosing-error concerns in the published record. It can be a legitimate option under supervision, but it does not carry the assurance behind an approved product.
Does the Ivim membership fee cover the medication?
No. The membership fee pays for clinical access, provider visits, and program support. Medication is a separate cost, which is the single biggest driver of what a member pays each month.
What should be checked before signing up?
Whether insurance covers weight-management medication, what the medication costs on top of the membership, and whether the drug offered is branded or compounded. Those three answers set the real monthly price.
By
By
